Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Avalanche Looks To Slow Snowball Effect With Annapurna Merger

This article was originally published in Scrip

Executive Summary

Avalanche Biotechnologies Inc. will acquire Annapurna Therapeutics SAS in an attempt to slow the snowball effect that wiped out 87% of Avalanche's value following disappointing clinical trial results for AVA-101 and a return to preclinical development for its lead gene therapy candidate.